Results: 712 (out of 33,793) transcripts were overexpressed in kidneys from diseased mice (age > 6 months). These transcripts were significantly enriched in the following pathways: response to type I interferons, antigen processing and presentation, activation and regulation of B cells, complement activation, and regulation of cytotoxicity mediated by T cells.

Proportions of renal CD8 T cells with an effector phenotype were significantly increased in the kidneys from mice compared to paired spleens. Proportions of renal effector CD8 T cells correlated significantly with transcripts involved in interferon signature, adaptive immune responses, cytotoxic T cells, chemokaxis, and correlated negatively with pathways associated with renal tubular cell functions.

Finally, we found a correlation between biological parameters of kidney function (plasma urea, albuminuria) and transcripts involved in pro-fibrotic pathways, chemokines and adaptive immune responses.

Conclusion: Our results confirm the link between the presence of activated immune effectors in the kidney and renal outcomes in a mouse model of SLE, similar to our previous observations in human LN, and warrant further functional studies on the role of kidney-infiltrating T and B cells in this model.

Acknowledgement: This research was funded in part by grants from Fonds de la Recherche Scientifique – FNRS, Fondation Roi Baudouin and Fondation Saint-Luc.

Disclosure of Interests: None declared

AB0187

CAN ARTIFICIAL INTELLIGENCE REPLACE MANUAL SEARCH FOR SYSTEMATIC LITERATURE REVIEW ON CUTANEOUS MANIFESTATIONS IN PRIMARY SJOGRÉN’S SYNDROME?

Laure Orgeote1,2, Nathan Fouquier1, Laurent Misery1, Pascal Redou1, Jacques-Olivier Pers1, Valérie Devauchelle-Pensec1, Alain Sarau1,1 CHU Brest, Brest, France; 2CHU Brest, Dermatology, Brest, France

Background: Manual systematic literature reviews are becoming increasingly challenging due to the sharp rise in publications. The task is particularly daunting when the study topic is complex.

Objectives: The primary objective of this literature review was to compare manual and in-house computer software retrieval of publications on the cutaneous manifestations of primary Sjögren’s Syndrome (pSS). The secondary objective was to evaluate the prevalence of cutaneous manifestations in pSS.

Methods: We compared manual searching and searching with the in-house computer software BIBOT (1) designed for article retrieval and analysis. Both methods were used for a systematic literature review on a complex topic i.e., the cutaneous manifestations of pSS. Articles published in French or English between 1 January 1990 and 30 May 2018 were sought.

Results: The manual search retrieved 855 articles and BIBOT 1042 articles. In all, 202 articles were then selecting by applying exclusion criteria. Among them, 155 were retrieved by both methods, 33 by manual search only, and 14 by BIBOT only. Further selection was performed by reading the 202 articles, which of 54 were deemed relevant, including 23 providing data on the prevalence of one or more cutaneous signs in a cohort of patients with pSS. Cohort sizes and the nature and prevalence of cutaneous manifestations varied across publications. In all, 52 cutaneous manifestations were reported, of which the most common were cutaneous vasculitis (561 patients), xerosis (651 patients), and annular erythema (215 patients).

Conclusion: Agreement was good between the two methods. BIBOT was faster and automatically classified the articles in a chart. Combining the two methods retrieved the largest number of publications. The prevalence of cutaneous manifestations in patients with pSS varied considerably across studies. The advanced machine learning techniques used in artificial intelligence hold promise for literature reviews.

REFERENCES

Disclosure of Interests: Laure Orgeote: None declared, Nathan Fouquier: None declared, Laurent Misery: None declared, Pascal Redou: None declared, Jacques-Olivier Pers: None declared, Valérie Devauchelle-Pensec: Grant/ research support from: Roche-Chugui. Speakers bureau: MSD, BMS, UCB, Roche, Alain Sarau Consultant for: Roche SAS, Speakers bureau: Chugui. Pharma France

AB0188

MOLECULAR NETWORKS IN MONOCYTES FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS RELATED TO THEIR IMMUNE RESPONSE AND MODULATORY EFFECTS OF ANTI-DSDNA ANTIBODIES AND MOLECULAR MECHANISMS UNDERLYING IN VIVO VIVOSTATIN TREATMENT

Alejandra M. Patricio-Trives1, Pérez Sánchez Laura1, María Galindo-Izquierdo2, María Luque-Tévar3, Alejandro Ibáñez-Costa4, Iván Arias de la Rosa5, María del Carmen Abalos-Aguilera5, Pedro Seguí Azpilicueta6, Nuria Barbaroja Puerto7, Eduardo Collantes-Echeverría8, María A. Aguirre-Sánchez2, Carla Pérez-Sánchez2, Chary Lopez-Pedreiras1,1 IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain; 2Hospital 12 de Octubre, Madrid, Spain

Objective: 1. To characterize the mRNAs and microRNAs transcriptions of monocytes from systemic lupus erythematosus (SLE) patients and their association with the pathophysiology of the disease. 2. To evaluate the role of anti-dsDNA antibodies in the regulation of these processes. 3. To investigate the molecular mechanisms involved in the efficacy of Fluvastatin in preventing the atherothrombotic risk.

Methods: Monocytes from peripheral blood of 81 SLE patients and 40 healthy donors (HD) were purified by negative immunomagnetic selection. Then, gene expression microarray (Agilent G4112F platform) and nCounter microRNA expression arrays (Nanostring) were performed. Functional categorization of altered genes and miRNAs was made using IPA software, and interaction networks were identified. Genes and miRNAs integrating the networks were validated in the whole cohort by RT-PCR. Predicted miRNA-mRNA interactions were tested by microRNA over-expression or inhibition experiments. Serum and cellular inflammatory and oxidative profiles were evaluated by multiplex assay, PCR and specific commercial kits, respectively; phosphorylation status of intracellular signaling proteins was analyzed by Pathscan array. To evaluate the clinical significance of the parameters analyzed, correlation and association studies were performed. Mechanistic studies were developed to typify the specific effects of the anti-dsDNA antibodies on monocytes. Besides, the beneficial effects of ex vivo Fluvastatin treatment on the monocyte molecular profiles were assessed.

Results: Microarray identified 553 altered genes in SLE monocytes. Relevant biofunctions and disorders on which these genes were involved included inflammatory, immunological, cardiovascular, neurological, renal and reproductive disease. Analysis of microRNA profiles showed altered expression of 35 miRNAs in SLE monocytes. Sixty-one genes were inversely correlated and predicted as CVD-related target genes of 26 differentially expressed miRNAs. Transfection studies confirmed the relationship between specific miRNAs and their identified target genes. Associations between these genes and miRNAs with the anti-dsDNA positivity, early atherosclerosis and nephropathy, along with correlations with disease activity (SLEDAI), activation of some intracellular signaling proteins, and levels of serum inflammatory and oxidative markers were demonstrated. In vitro studies demonstrated the specific modulation of several genes/miRNAs by anti-dsDNA, along with the increase of prothrombotic and proinflammatory mediators, the induction of apoptosis and the phosphorylation of intracellular proteins participating in renal and CVD-related signaling pathways. Besides, treatment of HD-monocytes with SLE patients’ serum after Fluvastatin supplementation prevented the proinflammatory altered gene/miRNA profiles induced by serum from those patients before treatment.

Conclusion: 1. Gene and microRNA expression profiles allowed the identification of relevant genes and pathways altered in monocytes of SLE patients, associated with the pathogenesis of the disease, and modulated by anti-dsDNA. 2. Specific microRNA-miRNA regulatory networks control the biological processes and factors related to the CV pathology in SLE, which are prevented by Fluvastatin treatment.

Acknowledgement: Funded by ISCIII, P115/01333, P118/00837 and RIER RD16/0012/0015 co-funded with FEDER
Disclosure of Interests: None declared

AB0189

DECREASED URINE SEMAPHORIN 3A SECRETION PREDICTS THE EXTENT OF RENAL DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Doron Pimam1, Merav Lifar2, Naaism Ezza3, Elias Toubl4, Amal Silawy1, Gleb Slodobin1, İzthak Rosner1, Michael Rosenbaum1, Abid Awisat1, Nael Boulama1, Lisa Kay1, Shira Ginsberg1, Nizar Jines2, Zahava Vadiac2,1 Bnai Zion Medical Center, Rheumatology, Ramat Gan, Israel; 3Bnai Zion Medical Center, Division of Allergy and Clinical Immunology, Haifa, Israel

Background: Semaphorins are a family of proteins, involved in axon-guidance, malignancy spread and angiogenesis. Semaphorin 3A (sema3A) is recognized also as “immune semaphorin”, it is expressed on regulatory T cells and has been
shown to enhance their inhibitory effect of CD4+ T cell pro-inflammatory function and replication. We have reported a decreased serum levels of sema3A in systemic lupus erythematosus (SLE) compared to healthy controls and in correlation with SLE disease activity [1]. Sema3A was found to be over expressed in podocytes and epithelial cells in in animal models with diabetic nephropathy. Increased urinary sema3A was also detected in diabetic patients with proteinuria and in contrast-induced acute renal injury [2-3].

**Objectives:** To assess urine sema3A secretion in SLE patients with and without renal involvement compared to rheumatoid arthritis patients as disease control and healthy controls.

**Methods:** 50 ml of fresh urine samples were collected, centrifuged and the supernatant was then concentrated up to 50 times the initial concentration and subjected to specific human Sema3A ELISA kit (MBS732622, San Diego, CA, USA).

**Results:** Thirty-eight lupus patients fulfilling the 2012 SLICC criteria were recruited, 33 (87%) of whom were women, at a mean age of 35±12 years. Eight patients had active nephritis (21%) and additional 5 had a history of nephritis but were in remission. APLA was diagnosed in 13 (34%) of patients. Disease activity was evaluated by the Systemic lupus erythematosus disease activity index 2000 (SLEDAI 2K) and was B.5.7.7.

Sema3A was lower in lupus patients compared to rheumatoid arthritis and healthy controls, 4.3±3.9 ng/mL, 8.5±2.7 ng/mL, 9.855±1.7 ng/mL, p=0.0006. Lupus nephritis patients demonstrated lower urine sema3A concentration compared to lupus patients without renal involvement 4±3.4 ng/mL, 6.5±3.8 ng/mL, p=0.03. Sema 3A was reversely correlated with proteinuria n=0.43, p=0.006 and SLEDIACK -0.3, p=0.04, but not with creatinine concentration, disease duration and complement concentration. There was no difference in urinary sema3A between SLE patients with or without APLA syndrome.

**Conclusion:** Urinary excretion of Sema 3A was found to be decreased in the SLE patients with renal disease, reversely correlating with disease activity and proteinuria. These findings are in line with previous reports of decreased serum level of Sema3A in SLE, that may result in reduced efficacy of regulatory T cells, driving autoimmunity and kidney damage. The discrepancy between low sema3A urinary excretion in SLE nephropathy and increased urinary secretion in other “non-auto immune” conditions with renal damage, suggests that sema3A in the kidneys is protective in autoimmune diseases and detrimental in “non-auto immune” conditions. This differential effect of sema3A may has to do with different populations of effector cells and different expression of sema3A receptors (norrin-lin1). Further studies should evaluate semaphorin 3A role in lupus nephritis and its potential as a treatment option.

**REFERENCES**


Disclosure of Interests: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.3456

**AB0190**

CROSSTALK BETWEEN SALIVARY GLAND EPITHELIAL CELLS AND B LYMPHOCYTES IN PRIMARY SJÖGREN’S SYNDROME

Elodie Rivière1,2, Juliette Pascaud1, Nicolas Tchitchek1, Nicolas Boudaoud1, Audrey Paletti1, Bineta Ly1, Alice Thai1, Norm Allaire1, Nicolas Tchitchek1, Saida Boudaoud1, Michael Mingueneau1, Gaetane Nocturne1, Xavier Mariette1

**Background:** Primary Sjögren’s syndrome (pSS) is an auto-immune disorder characterized by lymphocytic infiltrates and destruction of the salivary glands. Mechanisms leading to B lymphocytes chronic activation remain partially understood and we assumed that salivary gland epithelial cells (SGECs) might play a key role in B lymphocytes activation and differentiation.

**Objectives:** We aimed to study the interactions between SGECs from pSS patients or controls and B lymphocytes.

**Methods:** Patients with pSS according to 2016 EULAR/ACR criteria and controls with sicca symptoms were studied. RNAseq analysis was performed on SGECs and B lymphocytes sorted from salivary gland and blood using a FACSS ARIA. Enrichment analysis was performed using Ingenuity Pathway Analysis software. Validation of the results was performed by qPCR (Biornark technology).

**Results:** The RNAseq analysis of B lymphocytes sorted from salivary gland showed an up-regulation of CD40 and CD48 which are involved in their activation. The analysis of sorted SGECs highlighted IL-7, interferon (IFN) signaling pathways and genes potentially involved in immune responses, including HLA-DR, B2T (bone marrow stromal cell antigen 2) and BAF53. Co-culture experiments showed an increase of B lymphocytes viability when co-cultured with SGECs compared to B lymphocytes cultured alone (p<0.05). Co-culture with SGECs from pSS compared to controls lead to an increased survival of B lymphocytes (calculated as the percentage of alive co-cultured B lymphocytes – percentage of alive cultured alone B lymphocytes) without stimulation or stimulated with Poly (I:C) (p<0.01) (Figure 1A). Similarly, SGECs from pSS were more likely to induce higher activation of B lymphocytes compared to SGECs from controls, assessed by the percentage of CD38+ B lymphocytes (significant after stimulation with Poly (I:C)) (Figure 1B).

To determine whether the activation of B lymphocytes and SGECs required a direct cell contact, we used transwell experiments. Preliminary results suggested that the increase of B lymphocytes viability could depend mostly on soluble factors that are currently being identified and will be communicated at the congress.

**Disclosure of Interests:** Elodie Rivière: None declared, Juliette Pascaud: None declared, Nicolas Tchitchek: None declared, Saida Boudaoud: None declared, Audrey Paletti: None declared, Bineta Ly: None declared, Alice Thai Employee of: Alice Thai is employed by Biogen., Norm Allaire Employee of: Norm Allaire is employed by Biogen., Bernd Jagla: None declared, Michael Mingueneau Employee of: Michael Mingueneau is employed by Biogen., Gaetane Nocturne: None declared, Xavier Mariette Grant/research support from: Servier, Consultant for: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, UCB Pharma

**DOI:** 10.1136/annrheumdis-2019-eular.4121

**AB0191**

ENDOTHELIN-1 LEVEL IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, ITS ASSOCIATION WITH ENDOTHelial DYSFUNCTION AND Atherosclerosis

Serhi Shevchuk1, Inna Kuvkova1, Yulia Seched1, Olena Galustnova1, National Pirigov Memorial Medical University, Vinnitsia, Ukraine; 2Scientific and Research Institute of Invalid Rehabilitation on the base of National Pirigov Memorial Medical University, rheumatology, Vinnitsia, Ukraine; 3Scientific and Research Institute of Invalid Rehabilitation on the base of National Pirigov Memorial Medical University, rheumatology, Vinnitsia, Ukraine

**Background:** It is known that endothelin-1 is one of the leading factors in the development of coronary artery disease, acute myocardial infarction, atherosclerosis of cerebral and peripheral vessels, pulmonary hypertension, ischemic lesion